Skip to main content

Government officials will never ask you to transfer money or disclose bank log-in details over a phone call.

Call the 24/7 ScamShield Helpline at 1799 if you are unsure if something is a scam.

Agency for Care Effectiveness
  1. Home
  2. Healthcare professionals
  3. ACE Technology Guidances
  4. Drug Guidance
  5. Subcutaneous infliximab biosimilar for treating inflammatory conditions
Drug guidance

Subcutaneous infliximab biosimilar for treating inflammatory conditions

Condition

Endocrine and metabolic

13 September 2024

Published on 13 Sep 2024
Last Updated on 13 Sep 2024

Guidance Recommendations

The Ministry of Health’s Drug Advisory Committee has not recommended subcutaneous infliximab biosimilar (Remsima) for inclusion on the MOH List of Subsidised Drugs for treating rheumatoid arthritis, ankylosing spondylitis, psoriatic arthritis, plaque psoriasis, Crohn’s disease, and ulcerative colitis. The decision was based on unacceptable pricing proposal from the company.

Subcutaneous infliximab biosimilar for treating inflammatory conditions (Published 13 Sep 2024) [PDF, 89 KB]

Back to top